Notice of Preliminary Results

RNS Number : 1376W
Oxford Biomedica PLC
23 January 2013
 

 

 

 

 

 

 

Oxford BioMedica: Notice of Preliminary Results

Results date: 27 February 2013

 

 

Oxford, UK - 23 January 2013: Oxford BioMedica plc (LSE: OXB), the leading gene-based biopharmaceutical company, will be announcing its preliminary results for the twelve months ended 31 December 2012 on Wednesday, 27 February 2013.

 

An analyst briefing will be held at 09:30am GMT on Wednesday, 27 February 2013 at the offices of M:Communications, 11th Floor, CityPoint, 1 Ropemaker Street, London, EC2Y 9AW. An audio replay will be made available shortly after the presentation on the Company's website: www.oxfordbiomedica.co.uk

 

-Ends-

 

For further information, please contact:

 

 

Oxford BioMedica plc:

Lara Mott, Head of Corporate Communications

 

Tel: +44 (0)1865 783 000

 

Media Enquiries:

Mary Clark/Sarah Macleod/Claire Dickinson M:Communications

 

Tel: +44 (0)20 7920 2360

 

 

Notes to editors

 

1. Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

NOREAXFAAAEDEFF